Degarelix (FIRMAGON(R)) Vs Leuprolide (Lupron Depot(R)) In Patients With Advanced ...
Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in...
Medical News Today,
Sat Dec 05 04:42:11 PST 2009
• Found on Yahoo! News
Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced ...
BETHESDA, Md., Dec. 4 /PRNewswire/ -- Drs. Neal Shore and E.
redOrbit,
Fri Dec 04 07:24:50 PST 2009
• Found on Yahoo! News
Topix.net
360,000 news channels, from Autos to your ZIP code.
• Found on Topix News
Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced ...
Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Pha...
PR Newswire via Yahoo! Finance,
Fri Dec 04 06:07:00 PST 2009
• Found on Yahoo! News
Significant potential of late- and mid-stage Novartis hematology portfolio to be s...
Novartis announced today that new data, including a late-breaking presentation on Tasigna® 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's h...
PR Newswire via Yahoo! Finance,
Tue Dec 01 22:25:00 PST 2009
• Found on Yahoo! News
Sanofi-aventis: Multaq(R) Approved In The European Union For Patients With Atrial ...
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the European Commission has granted marketing authorization for Multaq(R) (dronedarone 400mg Tablets) in all 27 European member s...
Medical News Today,
Tue Dec 01 04:41:26 PST 2009
• Found on Yahoo! News
Sanofi-aventis' atrial fibrillation drug dronedarone gets European marketing nod
Sanofi-aventis announced that the European Commission has granted marketing authorization for Multaq (dronedarone
PharmaBiz,
Mon Nov 30 19:51:25 PST 2009
• Found on Yahoo! News
Europe's device therapy use for heart failure doubles 2004-2008, some countries ha...
The use of implantable devices for the treatment of heart failure increased "enormously" in Europe between the years 2004 and 2008, but there still remain large differences between countrie...
EurekAlert!,
Mon Nov 30 10:28:38 PST 2009
• Found on Yahoo! News
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial ...
PARIS, November 30 /PRNewswire-FirstCall/ -- - First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announce...
redOrbit,
Mon Nov 30 03:07:50 PST 2009
• Found on Yahoo! News
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial ...
- First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has gran...
Thaipr.net,
Mon Nov 30 01:17:15 PST 2009
• Found on Yahoo! News
Sanofi-aventis: Multaq(R) Approved in the European Union.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone - 400mg Tablets) in all 27 European ...
Stock World,
Sun Nov 29 23:29:54 PST 2009
• Found on Yahoo! News
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial ...
Paris, November 30 (ots/PRNewswire) - - First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: ...
FinanzNachrichten,
Sun Nov 29 23:26:59 PST 2009
• Found on Yahoo! News
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial ...
Paris, November 30 (ots/PRNewswire) - - First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today...
Presseportal,
Sun Nov 29 23:17:09 PST 2009
• Found on Yahoo! News
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial ...
Sanofi-aventis announced today that the European Commission has granted marketing authorization for Multaq in all 27 European member states. This approval follows the European Commission po...
CNW Group via Yahoo! Finance,
Sun Nov 29 23:26:00 PST 2009
• Found on Yahoo! News
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial ...
-
PR Newswire via Yahoo! Finance,
Sun Nov 29 23:09:00 PST 2009
• Found on Yahoo! News
Europe's device therapy use for heart failure doubles 2004-2008, some countries ha...
The use of implantable devices for the treatment of heart failure increased "enormously" in Europe between the years 2004 and 2008, but there still remain large differences between countrie...
PhysOrg,
Mon Nov 30 11:42:56 PST 2009
• Found on Yahoo! News
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial ...
PARIS, November 30 /PRNewswire/ -- - First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today th...
ITNews,
Sun Nov 29 23:14:05 PST 2009
• Found on Yahoo! News